GlassScriptPhysician profile
Suela Omeri
NPI 1073213088
$2,968.33
in general payments reported to CMS, 2019-2025
22 companies · $2,336 in 2025
The $2,336 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $632 · 2025: $2,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,936 · Education: $32.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,936.03 |
| Education | $32.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $527.42 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $347.26 | 2024-2025 | Xifaxan, Relistor |
| Abbvie INC. | $312.07 | 2024-2025 | |
| Janssen Biotech, INC. | $295.48 | 2024-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $205.62 | 2024-2025 | Livdelzi |
| Pfizer INC. | $192.23 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $184.80 | 2025 | Voquezna |
| Ardelyx, INC. | $152.16 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $123.77 | 2024-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $117.21 | 2025 | Iqirvo |
| Genzyme Corporation | $108.71 | 2024-2025 | |
| Madrigal Pharmaceuticals | $68.77 | 2025 | Rezdiffra |
| Lilly USA, LLC | $62.74 | 2024-2025 | Omvoh, Zepbound |
| Ferring Pharmaceuticals INC. | $49.32 | 2024-2025 | Rebyota |
| Intercept Pharmaceuticals, INC. | $42.80 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $34.17 | 2024-2025 | Wegovy, Saxenda |
| Qol Medical, LLC | $32.59 | 2024 | Sucraid |
| Currax Pharmaceuticals LLC | $30.77 | 2024-2025 | Contrave |
| Celgene Corporation | $27.22 | 2024 | Zeposia |
| Celltrion USA INC. | $19.88 | 2024 | Zymfentra |
| Ironwood Pharmaceuticals, INC | $18.28 | 2024 | |
| Orphalan INC | $15.06 | 2025 | Cuvrior |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suela Omeri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.